These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26915463)

  • 101. Unusual cause of sinusitis and cough.
    Aldana G; Jimenez CA; Moran C
    BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 30030254
    [No Abstract]   [Full Text] [Related]  

  • 102. Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia.
    Eyre TA; Lamanna N; Roeker LE; Ujjani CS; Hill BT; Barr PM; Lansigan E; Cheson BD; Yazdy M; Allan JN; Rhodes J; Schuster SJ; Nabhan C; Skarbnik A; Leslie L; Islam P; Whitaker K; Coombs CC; Tuncer HH; Pagel JM; Jacobs R; Winter AM; Bailey N; Sitlinger A; Schuh AH; Follows G; Fox CP; Brander DM; Shadman M; Mato AR
    Haematologica; 2021 Jan; 106(1):284-287. PubMed ID: 32079693
    [No Abstract]   [Full Text] [Related]  

  • 103. Increased lymphocyte cell size with blastoid morphology associated with splenic rupture following cessation of ibrutinib.
    Porpaczy E; Skrabs C; Schwarzinger I; Augustin D; Thalhammer R; Jaeger U
    Br J Haematol; 2018 May; 181(4):431. PubMed ID: 29479671
    [No Abstract]   [Full Text] [Related]  

  • 104. Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients.
    Boissard F; Fournié JJ; Quillet-Mary A; Ysebaert L; Poupot M
    Blood Cancer J; 2015 Oct; 5(10):e355. PubMed ID: 26430726
    [No Abstract]   [Full Text] [Related]  

  • 105. Changes in the treatment landscape for chronic lymphoid leukemia.
    Foà R
    N Engl J Med; 2014 Jul; 371(3):273-4. PubMed ID: 25014693
    [No Abstract]   [Full Text] [Related]  

  • 106. Understanding cancer cell survival is key to patient survival.
    Fegan C; Pepper C
    Lancet Oncol; 2015 Feb; 16(2):122-4. PubMed ID: 25638674
    [No Abstract]   [Full Text] [Related]  

  • 107. Symptomatic leptomeningeal carcinomatosis: a rare presentation of chronic lymphocytic leukaemia relapse.
    Batayneh O; Lin A; Abu-Jaradeh O; Wu P; Villamar MF; Sharma P
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35675961
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Ibrutinib does not affect ristocetin-induced platelet aggregation evaluated by light transmission aggregometry in chronic lymphocytic leukemia patients.
    Alberelli MA; Innocenti I; Autore F; Laurenti L; De Candia E
    Haematologica; 2018 Mar; 103(3):e119-e122. PubMed ID: 29242303
    [No Abstract]   [Full Text] [Related]  

  • 109. Bing-Neel syndrome presenting as isolated CNS lymphoplasmacytic lymphoma: A case report and review of the literature.
    Grainger BT; Issa S
    J Clin Neurosci; 2020 Jan; 71():277-280. PubMed ID: 31862225
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Ibrutinib in CLL: 2 sides of the same coin.
    Bosch F; Abrisqueta P
    Blood; 2015 Nov; 126(19):2173-4. PubMed ID: 26542251
    [No Abstract]   [Full Text] [Related]  

  • 111. Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia.
    Pouvaret A; Guery R; Montillet M; Molina TJ; Duréault A; Bougnoux ME; Galliot R; Lanternier F; Delarue R; Lortholary O
    Clin Microbiol Infect; 2019 Jun; 25(6):771-773. PubMed ID: 30703527
    [No Abstract]   [Full Text] [Related]  

  • 112. A rare colonic manifestation of chronic lymphocytic leukemia.
    Namn Y; Furman RR; Crawford C
    Leuk Lymphoma; 2019 Jan; 60(1):226-229. PubMed ID: 30488746
    [No Abstract]   [Full Text] [Related]  

  • 113. [Application of ibrutinib in primary central nervous system lymphoma].
    Pang DW; Chen FL; Li WY
    Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):348-350. PubMed ID: 32447944
    [No Abstract]   [Full Text] [Related]  

  • 114. The GLOW trial in chronic lymphocytic leukaemia.
    van Gelder M; Hoogendoorn M; Te Raa D
    Lancet Oncol; 2024 Feb; 25(2):e55. PubMed ID: 38301697
    [No Abstract]   [Full Text] [Related]  

  • 115. The GLOW trial in chronic lymphocytic leukaemia.
    Fey M
    Lancet Oncol; 2024 Feb; 25(2):e54. PubMed ID: 38301696
    [No Abstract]   [Full Text] [Related]  

  • 116. Chronic lymphocytic leukaemia therapy: is less more?
    Walter HS; Dyer MJS
    Lancet Haematol; 2022 Mar; 9(3):e169-e171. PubMed ID: 35240069
    [No Abstract]   [Full Text] [Related]  

  • 117. Leptomeningeal involvement in B-cell chronic lymphocytic leukemia: a case report and review of the literature.
    de Souza SL; Santiago F; Ribeiro-Carvalho Mde M; Arnóbio A; Soares AR; Ornellas MH
    BMC Res Notes; 2014 Sep; 7():645. PubMed ID: 25218117
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Comment on: "UGT2B17 modifies drug response in chronic lymphocytic leukaemia".
    Papamichos SI; Jungbauer C
    Br J Cancer; 2020 Oct; 123(8):1345-1346. PubMed ID: 32704175
    [No Abstract]   [Full Text] [Related]  

  • 119. Reply to Comment on "UGT2B17 modifies drug response in chronic lymphocytic leukaemia".
    Guillemette C; Rouleau M; Vanura K; Lévesque É
    Br J Cancer; 2020 Oct; 123(8):1347-1348. PubMed ID: 32704176
    [No Abstract]   [Full Text] [Related]  

  • 120. BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib.
    Jackson RA; Britton RG; Jayne S; Lehmann S; Cowley CM; Trethewey CS; Smith VM; Schmid R; Fegan C; Walter HS; Dyer MJS
    Blood Adv; 2023 Jul; 7(14):3378-3381. PubMed ID: 37257190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.